SCHEMBL25609164

SCHEMBL25609164

Clc1cncc(-c2cccnn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ FGFR1 P11362 1/20 0.38
▸ NPY5R Q15761 1/20 0.38
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ AOC3 Q16853 1/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ MAPT P10636 4/20 0.35
▸ PDE2A O00408 1/20 0.35
▸ HCAR2 Q8TDS4 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ TEK Q02763 1/20 0.35
▸ SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31277575 1.00 GRM5 (0.43) GRM5MKNK1MKNK2FGFR1NPY5R
SCHEMBL25605950 0.79 CYP2A6 (0.42) NPY5RCYP11B1CYP11B2NPC1RAB9A
SCHEMBL913810 0.78 NOTUM (0.47) GRM5NPY5RNPC1RAB9AMAPT
SCHEMBL30661720 0.75 L3MBTL1 (0.49) GRM5NPC1RAB9ADHODHMAPT
SCHEMBL218007 0.75 L3MBTL1 (0.49) GRM5NPC1RAB9ADHODHMAPT
SCHEMBL4701329 0.75 CYP2A6 (0.59) MKNK1MKNK2NPC1RAB9AMAPT
SCHEMBL20873079 0.75 CYP2A6 (0.50) GRM5DHODHMAPTALDH1A1CYP1A2
SCHEMBL30297729 0.75 CYP2A6 (0.50) GRM5DHODHMAPTALDH1A1CYP1A2
SCHEMBL28210972 0.75 NPY5R (0.42) FGFR1NPY5RCYP11B1CYP11B2NPC1
SCHEMBL15594502 0.74 MKNK1 (0.41) MKNK1MKNK2FGFR1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 — — US disclosed
EP-4444309-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
WO-2023107603-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107603-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP GRM5 525/4885MKNK1 1592/4885MKNK2 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback